A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MF.
Veeraraghavan J, et al. Among authors: davis r.
Clin Cancer Res. 2023 Aug 15;29(16):3101-3109. doi: 10.1158/1078-0432.CCR-22-3753.
Clin Cancer Res. 2023.
PMID: 37195235
Free PMC article.